BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION

被引：0
|
作者：
Hude, I. [1 ,2 ]
Sasse, S. [2 ]
Broeckelmann, P. J. [2 ]
von Tresckow, B. [2 ]
Momotow, J. [2 ]
Engert, A. [2 ]
Borchmann, S. [2 ]
机构：
[1] Univ Hosp Ctr Zagreb, Div Hematol, Dept Internal Med, Zagreb, Croatia
[2] Univ Hosp Cologne, Dept Internal Med 1, GHSG, Cologne, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1119
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [1] Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition
    Hude, Ida
    Sasse, Stephanie
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Momotow, Jesko
    Engert, Andreas
    Borchmann, Sven
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (06) : 837 - 840
  • [2] Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors
    Borchmann, S.
    Hude, I.
    Sasse, S.
    Broeckelmann, P.
    von Tresckow, B.
    Momotow, J.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 142 - +
  • [3] Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma
    Calabretta, Eleonora
    di Trani, Martina
    Corrado, Francesco
    Sollini, Martina
    Cristaldi, Vanessa
    Marino, Fabrizio
    di Bergamo, Lodovico Terzi
    Bruscaggin, Alessio
    Pirosa, Maria Cristina
    Bramanti, Stefania
    Chiti, Arturo
    Rossi, Davide
    Carlo-Stella, Carmelo
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 514 - 524
  • [4] PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Godfrey, James
    Siddiqi, Tanya
    Salhotra, Amandeep
    Chen, Robert
    Smith, Eileen
    Popplewell, Leslie L.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : E893 - E897
  • [5] lTumor Microenvironment in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma before and after Anti-PD-1 Therapy
    Gusak, Artem A.
    Lepik, Kirill V.
    Mikhailova, Natalia B.
    Kondakova, Elena
    Zalaylov, Yuri R.
    Popova, Marina O.
    Ionova, Tatiana I.
    Kulagin, Aleksandr D.
    Afanasyev, Boris V.
    Baykov, Vadim
    BLOOD, 2020, 136
  • [6] Dominant negative PD1 armored CART cells induce remission in relapsed or refractory Non-Hodgkin Lymphoma (NHL) patients
    Pu, Cheng Fei
    Xiao, Lei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients
    Yuan, Yan
    Huang, Liansheng
    Su, Yang
    Pu, Chengfei
    Ding, Tianling
    Xiao, Xibin
    Jin, Lina
    Cao, Zhiyuan
    Wu, Ting
    Chen, Tong
    Ding, Luying
    Zhang, Xiaohong
    Lan, Haifeng
    Wu, Zhao
    Xiao, Lei
    MOLECULAR THERAPY, 2020, 28 (04) : 334 - 334
  • [8] Improving the outcome in patients with relapsed/refractory classical Hodgkin lymphoma undergoing allogeneic stem cells transplantation
    Afanasyev, Boris
    Borzenkova, Eugenia
    Lepik, Kirill
    Darskaya, Elena
    Pirogova, Olga
    Moiseev, Ivan
    Mikhailova, Natalia
    Rogacheva, Julia
    Kozlov, Andrew
    Gevorgian, Asmik
    Zalyalov, Yuri
    Alyansky, Alexander
    Popova, Marina
    Bondarenko, Sergey
    BONE MARROW TRANSPLANTATION, 2018, 53 : 610 - 612
  • [9] A REAL WORLD EXPERIENCE WITH PD1 INHIBITORS IN RELAPSED/REFRACTORY HODGKINS LYMPHOMA
    Kakkar, Disha
    Agarwal, Narendra
    Panda, Tribikram
    Singh, Aakanksha
    Halder, Rohan
    Palatty, Roy J.
    Bhurani, Dinesh
    BONE MARROW TRANSPLANTATION, 2024, 59 : 490 - 490
  • [10] An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma
    Wight, Joel C.
    Hawkes, Eliza A.
    Berlangieri, Salvatore U.
    Khor, Richard
    Grigg, Andrew P.
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2749 - 2751
12345